• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Fresenius Kabi has a Class I recall of Ivenix Infusion System software

April 18, 2024 By Danielle Kirsh

Fresenius Kabi Ivenix infusion system
The Ivenix infusion system. [Image courtesy of Fresenius Kabi]
The FDA this week labeled Fresenius Kabi’s recall of some Ivenix Infusion Systems (IIS) as Class I, the most serious kind.

Fresenius Kabi USA issued the recall of Ivenix Infusion System LVP software, its infusion pump software, due to an issue of multiple software anomalies occurring that can potentially result in serious patient harm or death.

The company issued the recall on March 7, 2024. It affects 17 products under the name LVP Software of the Ivenix Infusion System (IIS), Version 5.8.0, with distribution dates March 6, 2023 to March 20, 2024. There have been no reports of injuries or deaths associated with this issue, according to the FDA warning letter.

Fresenius Kabi will remedy the issue by releasing a new software version for the Ivenix Large Volume Pump. This recall affects people who are treated in a healthcare setting using the system and healthcare personnel who use the IIS to deliver blood and medications to patients in healthcare settings.

This is Fresenius Kabi’s second Ivenix recall in recent months. In January, the FDA labeled the company’s recall of the LVP-0004 model of the Ivenix large-volume pumps as Class I. The company recalled the pump because some units have mechanical issues with the fluid valve pins. This issue may cause the pins — located inside the pump’s internal housing — to not move properly. Instead of going where they should, the pins could impact the side of a sensor.

Fresenius Kabi’s Ivenix Infusion System is indicated for use in a hospital and in outpatient care environments for the controlled administration of fluids to patients through accepted methods, such as intravenous lines, arterial lines, epidurals and subcutaneous delivery. The fluids typically include medications, blood products or other agents needed to treat adult and pediatric patients.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance, Technology Tagged With: FDA, Fresenius Kabi

IN CASE YOU MISSED IT

  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance
  • Medtronic moves to divest final stake in MiniMed
  • Dexcom adds former Stryker CFO to board
  • MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS